Study Shows Postmenopausal Women Taking Anastrozole As A Chemopreventive Treatment Do Not Have Impaired Cognitive Performance, Cancer Research UK Psychosocial Oncology Group at the University of Sussex Study

Queen Mary -- NEW results of a sub-study carried out as part of a worldwide breast cancer prevention study (IBIS-II) show that after two years of taking the aromatase inhibitor, anastrozole, postmenopausal women at high risk of breast cancer do not have impaired cognitive performance.